<DOC>
	<DOCNO>NCT00412542</DOCNO>
	<brief_summary>Objectives : 1.1 To determine efficacy , measure 6 month progression-free survival , therapy thalidomide combine CPT-11 treatment patient recurrent and/or progressive malignant glioma . 1.2 To determine rate measureable clinical response patient treat Thalidomide CPT-11 . 1.3 To determine Thrombotic thrombocytopenic purpura ( TTP ) , overall survival unexpected toxicity Thalidomide CPT-11 use recurrent malignant glioma . 1.4 To determine change dynamic magnetic resonance imaging ( MRI ) surrogate marker treatment effect .</brief_summary>
	<brief_title>Thalidomide Temozolomide Camptothecin-11 ( CPT-11 ) Patients With Gliomas</brief_title>
	<detailed_description>Thalidomide drug interfere growth blood vessel . Thalidomide may help decrease blood supply tumor make unable grow . CPT-11 drug design stop cancer cell divide . All participant take thalidomide capsule mouth every evening bedtime . You begin 1 capsule every night first week increase 2 capsule every night week 3 capsule night third week . After , increase dose 4 capsule night rest study . The dosage may adjust experience severe side effect . In addition thalidomide , receive treatment CPT-11 continuous injection vein 90 minute week 4 week follow 2 week rest drug . This 6 week period call course therapy . The course therapy repeat long disease respond treatment 2 year . THIS IS AN INVESTIGATIONAL STUDY . Both drug commercially available . Thalidomide CPT-11 FDA approve treatment cancer . The combination drug investigational . Up 78 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Is age limit ? No 1 . Patients histologically prove supratentorial malignant primary glioma ( Glioblastoma multiforme ( GBM ) , Gliosarcoma ( GS ) Anaplastic astrocytoma ( AA ) , Anaplastic oligodendroglioma ( AO ) , mixed anaplastic glioma ( MAG ) ) eligible protocol . 2 . Patients must show unequivocal evidence tumor recurrence progression MRI scan radiation therapy . 3 . Patients GBM stratum may treatment 2 prior relapse ; AA stratum , limitation number relapse provide eligibility criterion particularly functional status meet . 4 . All patient must sign informed consent . 5 . The baseline onstudy MRI perform within 14 day prior registration stable decrease steroid dosage . 6 . Patients undergone recent resection recurrent progressive tumor eligible . 7 . Patients must life expectancy &gt; 8 week . 8 . Patients must Karnofsky performance status &gt; = 70 9 . Patients must recover toxic effect prior therapy : 4 week prior cytotoxic therapy and/or least two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , cisretinoic acid , etc . ( radiosensitizer count ) . Patients receive either Temozolomide CPT11 nontherapeutic purpose ( presurgically obtain pharmacology data agent ) eligible study entry provide recovered toxic effect agent . 10 . Patients must adequate bone marrow function ( Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 platelet count &gt; 100,000/mm3 ) , adequate liver function ( alanine aminotransferase ( ALT SGPT ) alkaline phosphatase &lt; 2 time normal , bilirubin &lt; 1.5 mg/dl ) , adequate renal function ( blood urea nitrogen ( BUN ) creatinine &lt; 1.5 time institutional normal ) prior start therapy . 11 . Patients must pregnant must practice adequate contraception study 2 month participation study . 1 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible . 2 . Patients must : ) active infection b ) disease obscure toxicity dangerously alter drug metabolism c ) serious intercurrent medical illness . ) prior recurrence CPT11 ( CPT11 + Thalidomide arm ) ( prior treatment thalidomide permit ) . e ) grade 2 high peripheral neuropathy . Patients receive Temozolomide CPT11 nontherapeutic purpose ( eg. , part pharmacology study without therapeutic intent ) remain eligible enrollment study . 3 . No exclusion study base race . Minorities actively recruit participate . The malignant glioma patient population treat MDACC past year follow : American Indian Alaskan Native 0 Asian Pacific Islander &lt; 2 % Black , Hispanic Origin 3 % Hispanic 6 % White , Hispanic Origin 88 % Other Unknown 2 % Total100 %</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Glioma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Thalomid</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>malignant glioma</keyword>
</DOC>